Inducible Mouse Models for Cancer Drug Target Validation

Overview

Journal J Cancer Prev

Specialty Oncology

Date 2017 Jan 6

PMID 28053958

Citations 6

Authors

Joseph H Jeong

Affiliations

Soon will be listed here.

Abstract

Genetically-engineered mouse (GEM) models have provided significant contributions to our understanding of cancer biology and developing anticancer therapeutic strategies. The development of GEM models that faithfully recapitulate histopathological and clinical features of human cancers is one of the most pressing needs to successfully conquer cancer. In particular, doxycycline-inducible transgenic mouse models allow us to regulate (induce or suppress) the expression of a specific gene of interest within a specific tissue in a temporal manner. Leveraging this mouse model system, we can determine whether the transgene expression is required for tumor maintenance, thereby validating the transgene product as a target for anticancer drug development (target validation study). In addition, there is always a risk of tumor recurrence with cancer therapy. By analyzing recurrent tumors derived from fully regressed tumors after turning off transgene expression in tumor-bearing mice, we can gain an insight into the molecular basis of how tumor cells escape from their dependence on the transgene (tumor recurrence study). Results from such studies will ultimately allow us to predict therapeutic responses in clinical settings and develop new therapeutic strategies against recurrent tumors. The aim of this review is to highlight the significance of doxycycline-inducible transgenic mouse models in studying target validation and tumor recurrence.

Citing Articles

Developing Bottom-Up Induced Pluripotent Stem Cell Derived Solid Tumor Models Using Precision Genome Editing Technologies.

Becklin K, Draper G, Madden R, Kluesner M, Koga T, Huang M CRISPR J. 2022; 5(4):517-535.

PMID: 35972367 PMC: 9529369. DOI: 10.1089/crispr.2022.0032.

Targeting the ESCRT-III component CHMP2A for noncanonical Caspase-8 activation on autophagosomal membranes.

Hattori T, Takahashi Y, Chen L, Tang Z, Wills C, Liang X Cell Death Differ. 2020; 28(2):657-670.

PMID: 32807832 PMC: 7862398. DOI: 10.1038/s41418-020-00610-0.

Direct activation of PP2A for the treatment of tyrosine kinase inhibitor-resistant lung adenocarcinoma.

Tohme R, Izadmehr S, Gandhe S, Tabaro G, Vallabhaneni S, Thomas A JCI Insight. 2019; 4(4).

PMID: 30830869 PMC: 6478418. DOI: 10.1172/jci.insight.125693.

Gain-of-Function Genetic Models to Study FSH Action.

McDonald R, Sadler C, Kumar T Front Endocrinol (Lausanne). 2019; 10:28.

PMID: 30792692 PMC: 6374295. DOI: 10.3389/fendo.2019.00028.

Translational research in radiation-induced DNA damage signaling and repair.

Nickoloff J, Boss M, Allen C, LaRue S Transl Cancer Res. 2018; 6(Suppl 5):S875-S891.

PMID: 30574452 PMC: 6298755. DOI: 10.21037/tcr.2017.06.02.

References

Aguirre A, Bardeesy N, Sinha M, Lopez L, Tuveson D, Horner J . Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev. 2003; 17(24):3112-26. PMC: 305262. DOI: 10.1101/gad.1158703. View

Imielinski M, Berger A, Hammerman P, Hernandez B, Pugh T, Hodis E . Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell. 2012; 150(6):1107-20. PMC: 3557932. DOI: 10.1016/j.cell.2012.08.029. View

Holzapfel B, Wagner F, Thibaudeau L, Levesque J, Hutmacher D . Concise review: humanized models of tumor immunology in the 21st century: convergence of cancer research and tissue engineering. Stem Cells. 2015; 33(6):1696-704. DOI: 10.1002/stem.1978. View

Sumimoto H, Miyagishi M, Miyoshi H, Yamagata S, Shimizu A, Taira K . Inhibition of growth and invasive ability of melanoma by inactivation of mutated BRAF with lentivirus-mediated RNA interference. Oncogene. 2004; 23(36):6031-9. DOI: 10.1038/sj.onc.1207812. View

Kwong L, Costello J, Liu H, Jiang S, Helms T, Langsdorf A . Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nat Med. 2012; 18(10):1503-10. PMC: 3777533. DOI: 10.1038/nm.2941. View

Herbst R, Fukuoka M, Baselga J . Gefitinib--a novel targeted approach to treating cancer. Nat Rev Cancer. 2004; 4(12):956-65. DOI: 10.1038/nrc1506. View

Perez-Lorenzo R, Zheng B . Targeted inhibition of BRAF kinase: opportunities and challenges for therapeutics in melanoma. Biosci Rep. 2011; 32(1):25-33. PMC: 3837566. DOI: 10.1042/BSR20110068. View

Langdon A, Crook N, Dantas G . The effects of antibiotics on the microbiome throughout development and alternative approaches for therapeutic modulation. Genome Med. 2016; 8(1):39. PMC: 4831151. DOI: 10.1186/s13073-016-0294-z. View

Li D, Shimamura T, Ji H, Chen L, Haringsma H, McNamara K . Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. Cancer Cell. 2007; 12(1):81-93. DOI: 10.1016/j.ccr.2007.06.005. View

10.

Richmond A, Su Y . Mouse xenograft models vs GEM models for human cancer therapeutics. Dis Model Mech. 2008; 1(2-3):78-82. PMC: 2562196. DOI: 10.1242/dmm.000976. View

11.

Ji H, Li D, Chen L, Shimamura T, Kobayashi S, McNamara K . The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell. 2006; 9(6):485-95. DOI: 10.1016/j.ccr.2006.04.022. View

12.

Muhsin M, Graham J, Kirkpatrick P . Gefitinib. Nat Rev Drug Discov. 2003; 2(7):515-6. DOI: 10.1038/nrd1136. View

13.

Saunders T . Inducible transgenic mouse models. Methods Mol Biol. 2010; 693:103-15. DOI: 10.1007/978-1-60761-974-1_7. View

14.

Boxer R, Jang J, Sintasath L, Chodosh L . Lack of sustained regression of c-MYC-induced mammary adenocarcinomas following brief or prolonged MYC inactivation. Cancer Cell. 2004; 6(6):577-86. DOI: 10.1016/j.ccr.2004.10.013. View

15.

Morton J, Bird G, Refaeli Y, Jimeno A . Humanized Mouse Xenograft Models: Narrowing the Tumor-Microenvironment Gap. Cancer Res. 2016; 76(21):6153-6158. PMC: 5093075. DOI: 10.1158/0008-5472.CAN-16-1260. View

16.

Karasarides M, Chiloeches A, Hayward R, Niculescu-Duvaz D, Scanlon I, Friedlos F . B-RAF is a therapeutic target in melanoma. Oncogene. 2004; 23(37):6292-8. DOI: 10.1038/sj.onc.1207785. View

17.

Moody S, Sarkisian C, Hahn K, Gunther E, Pickup S, Dugan K . Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. Cancer Cell. 2002; 2(6):451-61. DOI: 10.1016/s1535-6108(02)00212-x. View

18.

Theriot C, Koenigsknecht M, Carlson Jr P, Hatton G, Nelson A, Li B . Antibiotic-induced shifts in the mouse gut microbiome and metabolome increase susceptibility to Clostridium difficile infection. Nat Commun. 2014; 5:3114. PMC: 3950275. DOI: 10.1038/ncomms4114. View

19.

Makohon-Moore A, Iacobuzio-Donahue C . Pancreatic cancer biology and genetics from an evolutionary perspective. Nat Rev Cancer. 2016; 16(9):553-65. PMC: 5739515. DOI: 10.1038/nrc.2016.66. View

20.

Berger M, Locher G, Saurer S, Gullick W, Waterfield M, Groner B . Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res. 1988; 48(5):1238-43. View